PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
2024 · Oncogene · 6 citations
https://doi.org/10.1038/s41388-024-03130-0
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
7
Papers
16
Citations
3
h-index
0
i10-index
Hugo Berthou is an academic researcher from Hôpital Européen Georges-Pompidou. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Fibroblast Growth Factor Research & Lung Cancer Treatments and Mutations. The author has an h-index of 3, co-authored 6 publications.
Click to start Chat